Cellebrite DI (NASDAQ:CLBT) Reaches New 52-Week High - Time to Buy?

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report)'s share price reached a new 52-week high on Wednesday . The stock traded as high as $22.91 and last traded at $22.22, with a volume of 45847 shares trading hands. The stock had previously closed at $22.28.

Wall Street Analyst Weigh In

Several analysts have recently commented on CLBT shares. Craig Hallum lifted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. Needham & Company LLC increased their price target on Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, TD Cowen boosted their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cellebrite DI currently has an average rating of "Buy" and a consensus price target of $20.57.

Cellebrite DI Stock Up 2.8 %

The business's fifty day moving average is $20.52 and its two-hundred day moving average is $17.41. The stock has a market cap of $4.72 billion, a price-to-earnings ratio of -14.78, a PEG ratio of 2.71 and a beta of 1.46.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million for the quarter, compared to analysts' expectations of $102.06 million. During the same period last year, the firm earned $0.09 earnings per share. The company's revenue for the quarter was up 27.0% compared to the same quarter last year. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Institutional Trading of Cellebrite DI

Several hedge funds have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Cellebrite DI by 59.6% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock worth $33,000 after purchasing an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. increased its holdings in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after buying an additional 1,742 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Cellebrite DI in the second quarter valued at $71,000. Finally, Pathway Financial Advisers LLC lifted its holdings in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after buying an additional 4,118 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.